Kyowa Kirin published a patient-focused global consensus statement that highlights 12 recommendations for healthcare authorities, policymakers, hospitals, and clinicians to drive positive change for the global cutaneous T-cell lymphoma patient community.
Merck announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the phase III KeyVibe-010 trial.Â
ArteraAI has validated its first multimodal artificial intelligence digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence.Â
Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveiled the results of a new UCLA study examining the role of AI in identifying tumor margins and predicting the efficacy of focal therapy treatments.Â
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an aggressive type of brain tumor that is fast growing and difficult to treat.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.
A phase II trial evaluating setanaxib, Calliditas Therapeutics AB’s lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck shows positive topline results.Â
When cancer breaches the brain, it can be difficult for treatment to follow.
The Wistar Institute assistant professor Filippo Veglia and team have discovered a key mechanism of how glioblastoma suppresses the immune system so that the tumor can grow unimpeded by the body’s defenses.Â
The phase III KEYNOTE-B21 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, in combination with chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of disease-free survival for the treatment of patients with newly diagnosed, high-risk endometrial cancer after surgery with curative intent.
